Determine the necessary mass, volume, or concentration for preparing a solution.
Ublituximab (anti-CD20) (Ab175689) - ELISA
Immobilized Human CD20 VLP at 2.0 μg/mL can bind Ublituximab (anti-CD20) (Ab175689) with the EC₅₀ of 11.41 ng/mL.
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175689-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
Ab175689-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $279.90 | |
Ab175689-5mg | 5mg | In stock | $739.90 | |
Ab175689-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,189.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Ublituximab (anti-CD20) - Primary antibody, specific to MS4A1, >95%, high purity, Human IgG1 |
---|---|
Synonyms | APY antibody; ATOPY antibody; B lymphocyte antigen CD20 antibody; B Lymphocyte Cell Surface Antigen B1 antibody; B-lymphocyte antigen CD20 antibody; B-lymphocyte cell-surface antigen B1 antibody; B-lymphocyte surface antigen B1 antibody; B1 antibody; Bp 3 |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Specificity | MS4A1 |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | BINDING AGENT |
Mechanism of action | Antibody of CD20 (membrane-spanning 4-domains; subfamily A; member 1) |
Product Description | Ublituximab (anti-CD20) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab (anti-CD20) has anticancer effects. |
Isotype | Human IgG1 |
---|---|
Light Chain Type | kappa |
SDS-PAGE | 26.3 kDa (Light Chain) & 51.1 kDa (Heavy Chain), under reducing conditions; 191.4 kDa, under non-reducing conditions. |
Purification Method | Protein A purified |
Purity | >95% |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1174014-05-1 |
Ublituximab (anti-CD20) (Ab175689) - ELISA
Immobilized Human CD20 VLP at 2.0 μg/mL can bind Ublituximab (anti-CD20) (Ab175689) with the EC₅₀ of 11.41 ng/mL.
Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of Ramos cells labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ublituximab (anti-CD20) (Ab175689) - SEC
The purity of Ublituximab (anti-CD20) (Ab175689) is more than 95% verified by HPLC.
Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD20 with Ublituximab (anti-CD20) (Ab175689) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156250).
Ublituximab (anti-CD20) (Ab175689) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD20 (red) with Ublituximab (anti-CD20) (Ab175689) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 372 |
---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
ZJ24F0404184 | Certificate of Analysis | Apr 07, 2024 | Ab175689 |
ZJ24F0404183 | Certificate of Analysis | Apr 07, 2024 | Ab175689 |
ZJ24F0404182 | Certificate of Analysis | Apr 07, 2024 | Ab175689 |
1. de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R et al.. (2008) Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.. Br J Haematol, 140 (6): (635-43). [PMID:18302712] |
2. Le Garff-Tavernier M, Decocq J, de Romeuf C, Parizot C, Dutertre CA, Chapiro E, Davi F, Debré P, Prost JF, Teillaud JL et al.. (2011) Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.. Leukemia, 25 (1): (101-9). [PMID:20975664] |
3. Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E et al.. (2010) CD20 deficiency in humans results in impaired T cell-independent antibody responses.. J Clin Invest, 120 (1): (214-22). [PMID:20038800] |
4. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.. Clin Cancer Res, 10 (8): (2868-78). [PMID:15102696] |
5. Li B, Xu L, Pi C, Yin Y, Xie K, Tao F, Li R, Gu H, Fang J. (2017) CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.. Oncoimmunology, 7 (1): (e1380142). [PMID:29296544] |
6. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E et al.. (2015) Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.. Sci Transl Med, 7 (287): (287ra70). [PMID:25972002] |
7. Tedder, T F TF, Streuli, M M, Schlossman, S F SF and Saito, H H.. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, [PMID:2448768] |
8. Einfeld, D A DA, Brown, J P JP, Valentine, M A MA, Clark, E A EA and Ledbetter, J A JA.. (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.. The EMBO journal, [PMID:2456210] |
9. Tedder, T F TF, Klejman, G G, Schlossman, S F SF and Saito, H H.. (1989) Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1).. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:2466899] |
10. Stamenkovic, I I and Seed, B B.. (1988) Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein.. The Journal of experimental medicine, (1): [PMID:3260267] |
11. Tedder, T F TF, Boyd, A W AW, Freedman, A S AS, Nadler, L M LM and Schlossman, S F SF.. (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.. Journal of immunology (Baltimore, Md. : 1950), [PMID:3925015] |
12. Bubien, J K JK, Zhou, L J LJ, Bell, P D PD, Frizzell, R A RA and Tedder, T F TF.. (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.. The Journal of cell biology, [PMID:7684739] |
13. and Goldenberg, D M DM.. () The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.. Critical reviews in oncology/hematology, [PMID:11418316] |
14. and Dillman, R O RO.. () Monoclonal antibody therapy for lymphoma: an update.. Cancer practice, [PMID:11879282] |
15. . (2003) Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, [PMID:12899647] |
16. Li, Haidong H, Ayer, Linda M LM, Lytton, Jonathan J and Deans, Julie P JP.. (2003) Store-operated cation entry mediated by CD20 in membrane rafts.. The Journal of biological chemistry, (24): [PMID:12920111] |
17. Du, Jiamu J and 8 more authors.. (2008) Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide.. Molecular immunology, [PMID:18346788] |
18. Dörner, Thomas T and Burmester, Gerd R GR.. (2008) New approaches of B-cell-directed therapy: beyond rituximab.. Current opinion in rheumatology, [PMID:18388516] |
19. Polyak, Maria J MJ, Li, Haidong H, Shariat, Neda N and Deans, Julie P JP.. (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins.. The Journal of biological chemistry, (4): [PMID:18474602] |
20. Niederfellner, Gerhard G and 16 more authors.. (2011) Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.. Blood, (14): [PMID:21444918] |
21. Ivaldi, Corinne C and 6 more authors.. (2012) Proteomic analysis of S-acylated proteins in human B cells reveals palmitoylation of the immune regulators CD20 and CD23.. PloS one, [PMID:22615937] |
22. Phuah, Jiayao J and 10 more authors.. (2016) Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.. Infection and immunity, [PMID:26883591] |
23. Hayashi, Kazumi and 6 more authors.. (2016) Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.. Cancer science, [PMID:26920337] |